BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns

Investing.com Gold reports: BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns. Full body text was unavailable at ingest time, so this brief is based on headline context.